Literature DB >> 20802294

Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.

Stacey A Rizza1, Nathan W Cummins, David N Rider, Sahar Saeed, Marina B Klein, Andrew D Badley.   

Abstract

OBJECTIVE(S): HIV/hepatitis C virus (HCV) coinfection causes accelerated liver disease compared to HCV monoinfection, and only 30-60% of HIV/HCV-coinfected individuals respond to HCV therapy with pegylated interferon and ribavirin. There are currently no biomarkers that predict treatment response in these coinfected patients.
DESIGN: We investigated whether there is an association between HCV treatment response and SNPs of apoptosis-related genes during HIV/HCV coinfection.
METHOD: Genomic DNA from 53 HIV/HCV-coinfected individuals was analyzed for 82 SNPs of 10 apoptosis-related genes.
RESULTS: We found that the presence of the rs4242392 SNP in tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), which encodes for tumor necrosis factor-related apoptosis-inducing ligand receptor 1, predicts poor outcome to HCV therapy, in HIV/HCV-co-infected patients [odds ratio 5.91 (95% confidence interval 1.63-21.38, P = 0.007)].
CONCLUSION: The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802294      PMCID: PMC3149798          DOI: 10.1097/QAD.0b013e32833eacfd

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.

Authors:  Kerstin A Stegmann; Niklas K Björkström; Heike Veber; Sandra Ciesek; Peggy Riese; Johannes Wiegand; Johannes Hadem; Pothakamuri V Suneetha; Jerzy Jaroszewicz; Chun Wang; Verena Schlaphoff; Paraskevi Fytili; Markus Cornberg; Michael P Manns; Robert Geffers; Thomas Pietschmann; Carlos A Guzmán; Hans-Gustaf Ljunggren; Heiner Wedemeyer
Journal:  Gastroenterology       Date:  2010-02-02       Impact factor: 22.682

2.  TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis.

Authors:  Seiji Kikuchi; Ryuji Miyagishi; Toshiyuki Fukazawa; Ichiro Yabe; Yusei Miyazaki; Hidenao Sasaki
Journal:  J Neuroimmunol       Date:  2005-10       Impact factor: 3.478

3.  CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis.

Authors:  Jean-Philippe Herbeuval; Jean-Charles Grivel; Adriano Boasso; Andrew W Hardy; Claire Chougnet; Matthew J Dolan; Hideo Yagita; Jeffrey D Lifson; Gene M Shearer
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

4.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 5.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

6.  Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase.

Authors:  H Watanabe; F Wells; M E Major
Journal:  J Viral Hepat       Date:  2009-08-26       Impact factor: 3.728

7.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

8.  DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.

Authors:  Timothy R Morgan; Richard W Lambrecht; Herbert L Bonkovsky; Raymond T Chung; Deepa Naishadham; Richard K Sterling; Robert J Fontana; William M Lee; Marc G Ghany; Elizabeth C Wright; Thomas R O'Brien
Journal:  J Hepatol       Date:  2008-06-05       Impact factor: 25.083

9.  Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis.

Authors:  Alexandra Weber; Klaus-Peter Wandinger; Wolf Mueller; Orhan Aktas; Oliver Wengert; Eva Grundström; Stefan Ehrlich; Christine Windemuth; Tanja Kuhlmann; Thomas Wienker; Wolfgang Brück; Frauke Zipp
Journal:  J Neuroimmunol       Date:  2004-04       Impact factor: 3.478

10.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

View more
  2 in total

1.  Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus.

Authors:  Meryem Timucin; Hakan Alagozlu; Semra Ozdemir; Ozturk Ozdemir
Journal:  Hepat Mon       Date:  2013-04-13       Impact factor: 0.660

Review 2.  Role of viral and host factors in interferon based therapy of hepatitis C virus infection.

Authors:  Muhammad Imran; Sobia Manzoor; Javed Ashraf; Madiha Khalid; Muqddas Tariq; Hafiza Madeha Khaliq; Sikandar Azam
Journal:  Virol J       Date:  2013-10-01       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.